1 Q1/15 – all rights reserved Zestagen S.A. Services Summary 2015 v6/Q1 15 Nassos Alevizopoulos, PhD, MBA Managing Partner

2 Q1/15 – all rights reserved Meta-plasis (trans-formation) at a glance boutique biotech & pharma consulting Support project mgmt. or investment decisions Sector dedication Analyze, integrate & transform Extreme focus on science (Medline, WIPO) Commercial & financial info (databases) Excellent value for money Minuscule team (EU/US) with broad international network Consultants with active executive roles Direct access to specialized associated networks We understand & get down into the project’s core science Virtual operations (timesheet, availability) Rapid turnaround what we do how we do it why us?

3 Q1/15 – all rights reserved Key Metaplasis people Nassos Alevizopoulos, PhD, MBAKostas Alevizopoulos, PhDAndrei Lyne, MBA CH USA 20y of experience in biopharmaceutical development (large molecules, devices) currently CEO of Zestagen SA (preclinical cancer mAb; CH) oversaw an orphan drug designation in pancreatic cancer COO/CEO positions in various biopharma companies (US/GR) cofounded startup companies Business Planning & Analysis with Novartis Brunner Prize for the best of 181 PhDs in Molecular Biology (Lausanne Univ.); also MBA from Lausanne 17y of experience in life sciences (drug development, small molecules, diagnostics) currently CEO of APIM Therapeutics AS (cancer biotech, Norway) partner at Ventac Partners previously CEO/CSO/Head of R&D in various biotech companies (US/CH/GR) cofounded startup companies Ph.D. in Molecular Oncology (Univ. of Lausanne) trained in European patent law (Univ. of Strasbourg) 12y with UBS Investment Bank in London & New York, most recently as Executive Director over 100 transactions across 25 countries for deals worth an aggregate $8 billion; currently CFO at Synpromics Ltd. Experience in biopharma, buy- side and sell-side M&A, IPOs, convertible bonds etc. BA from Oxford Univ. (Baker Scholarship) MBA in finance from New York Univ. (Directors Fellowship)

4 Q1/15 – all rights reserved 1. Metaplasis can assist academic institutions with tech transfer Technology appraisal Scientific analysis Intellectual Property / Freedom to Operate (FTO) analysis SWOT analysis Evaluation of partnering potential Tech valuation Tech agreement drafting (Sponsored Research, CRADA) Collaboration with Univ. Tech Transfer Office (TTO) academic discovery Commercializable? TTO Seed $ angels Spinoff formation

5 Q1/15 – all rights reserved 1. Metaplasis can assist academic institutions with tech transfer (cont’ed) Case study 1: NewCo formation around cutting-edge cancer IP Unique mAb against cancer IP licensed from a European Institution to NewCo Seed investor found Case study 2: a Scandinavian University Position novel anti-cancer therapeutics Case study 3: mandate from a group of Canadian investors (on going) Scout for promising tech in N. America for NewCo formation Case study 4: technology appraisal for a Chinese biopharma company Report & annexes delivered in 10 business days

6 Q1/15 – all rights reserved 2. Metaplasis can assist with preclinical drug development effort Drawing from hands-on experience (running our own companies) we can assist with: Preclinical development plan generation Outsourcing decisions (chose relevant Contract-Research Organizations) Scientific & regulatory preparation for Guidance Regulator meetings (Scientific Advice, Protocol Assistance, IND/IMPD) Case studies Assist a clinical CRO to attract an assignment by a vaccine developer for preclinical regulatory assistance

7 Q1/15 – all rights reserved Sample Preclinical Development Plan Time Actions Cost Incumbent Single Page format 2. Metaplasis can assist with preclinical drug development effort (cont’ed)

8 Q1/15 – all rights reserved 3. Metaplasis can assist with investment decisions Product/company valuations risk-adjusted NPV comparables EV/EBITDA Case study 1: Estimate value of a Scandinavian biotech company with rNPV Case study 2 EV/EBITDA analysis of a Greek healthcare takeover target c2: EV/EBITDA c1: rNPV

9 Q1/15 – all rights reserved 4. Metaplasis can assist with business development of market-ready products Strategy development for market-ready (i.e. approved) products entering new geographic markets Identification of potential partners (licensors, buyers/sellers) Development of client company materials (non-conf & conf) Deal Structures & Value Sharing (e.g. up-fronts vs. delayed payments) Network in Balkans, MENA, CIS, some EU countries, some States pharmaceuticals, medical devices, neutraceuticals, herbals

10 Q1/15 – all rights reserved Case: ranking candidate Greek distributors for an Asian company 4. Metaplasis can assist with business development of market-ready products (c’ed)

11 Q1/15 – all rights reserved Summary of Metaplasis Services 1.Technology appraisals (academic institutions, biotech, investors…) 2.Assistance with preclinical drug development (biotech) 3.Assistance with investment decisions (biotech, investors) 4.Business development (market-ready products for pharma, devices etc.)

12 Q1/15 – all rights reserved Zestagen S.A. Thank You Nassos Alevizopoulos, PhD, MBA Managing Partner